Clinical Trials Logo

Pentoxifylline clinical trials

View clinical trials related to Pentoxifylline.

Filter by:
  • None
  • Page 1

NCT ID: NCT05660694 Completed - Tumor Clinical Trials

Comparison of Triamcinolone With Pentoxifylline and Vitamin- E Efficacy in the Treatment of Stage 2 and 3 Oral Submucous Fibrosis

Start date: January 1, 2020
Phase: Phase 4
Study type: Interventional

To compare the efficacy of Triamcinolone with Pentoxifylline and Vitamin E in patients with stage two and three oral submucous fibrosis.

NCT ID: NCT02951299 Not yet recruiting - Acute Kidney Injury Clinical Trials

The Protective Effect of Pentoxifylline on Acute Kidney Injury

Start date: May 1, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

Acute kidney injury (AKI) has a frequency of 7.0 % in hospital inpatients and is especially common in critically ill patients, in whom the prevalence of acute kidney injury is greater than 40% at admission to the intensive care unit if sepsis is present. Therefore, alternative strategies are required to confer better or more complete renoprotection for those who suffered from AKI. There had been many studies demonstrated that the phosphodiesterase inhibitor pentoxifylline (PTX) is a potent anti-inflammatory, anti-proliferative, and anti-fibrotic agent capable of attenuating experimental renal disease such as drugs, ischemic and sepsis induced AKI. We thereby design this controlled, non-randomized clinical trial, aiming at investigating the potential renoprotective efficacy of PTX, as compared to placebo, in 200 patients with AKI.

NCT ID: NCT01472263 Completed - Physical Disability Clinical Trials

Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases

Pentox
Start date: September 2009
Phase: Phase 3
Study type: Interventional

In this study the investigators are going to evaluate the efficacy pentoxifyline in HTLV-1 patients with neurological diseases: HAM/TSP or neurogenic bladder. In some laboratory experiments the investigators observed that this drug had the capacity to reduce the immune response in HTLV-1 infected cells. Since the exacerbated immune response is know to cause neurological disease in patients with HTLV-1 the investigators hope that pentoxifyline can alleviate symptoms and delay the progress of HAM/TSP in patients.